



ALK  
Investor Relations Department  
BÅge Alle 6-8  
Horsholm DK-2970  
Denmark

Visit IR website [↗](#)

Sign-up for Email alerts [↗](#)

#### OMX: ALKB

|               |                            |
|---------------|----------------------------|
| Last Trade:   | 1172.00                    |
| Trade Time:   | 4:59 PM ET<br>Jul 19, 2018 |
| Change:       | 0.00 (0.000%)              |
| Day Range     | N/A - N/A                  |
| 52-Week Range | 646.00 -<br>1200.00        |
| Volume        | N/A                        |

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

## Company releases [\[ View all \]](#)

*May 4, 2018*

[Three-month interim report \(Q1\) 2018](#)

*May 1, 2018*

[Release date of three-month interim report \(Q1\) 2018 and audio cast](#)

*Apr 17, 2018*

[ALK's partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet](#)

*Apr 11, 2018*

[ALK announces allergy diagnostic partnership with Rellergen in China](#)

*Mar 20, 2018*

[Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff](#)

## Upcoming Events [\[ View all \]](#)

*Aug 15, 2018*

[Six-month interim report \(Q2\) 2018](#)

*Nov 9, 2018*

[Nine-month interim report \(Q3\) 2018](#)